D2C7-IT is under clinical development by Istari Oncology and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Glioblastoma Multiforme (GBM) have a 23% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how D2C7-IT’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
D2C7-IT overview
D2C7-IT is under development for the treatment of glioblastoma multiforme. D2C7-IT is administered intratumorally. The drug candidate targets both the wild type EGFR receptor (specifically expressed in astrocytoma and glioblastomas and the mutant EGFRvIII receptor, specifically expressed in glioblastomas. The drug candidate is a recombinant single-chain variable region antibody fragment from D2C7 hybridoma engineered to a disulfide stabilized linkage between variable and light domains to generate D2C7 (scdsFv) which is then connected to a truncated variant of Pseudomonas exotoxin A carrying a C-terminal KDEL peptide for improved intra-cellular transport (PE38KDEL).
The drug candidate was under development for malignant glioma.
Istari Oncology overview
Istari Oncology is developing novel immunotherapies for the treatment of solid tumors. The company is headquartered in Durham, North Carolina, the US.
For a complete picture of D2C7-IT’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
